SLC12A6

Across TCGA pan-cancer cohorts, SLC12A6 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SLC12A6 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SLC12A6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC12A6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

KIRC, MESO, and OV are the cancer types where SLC12A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	36	view →
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
OV	OS	Median	II,III,IV	0.023	0.844	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.749	0.550	.009	20	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.216	0.732	.018	6	view →
LIHC	DFS	Median	All	0.100	0.543	.038	6	view →
STAD	DFS	Median	All	1.000	0.390	.042	5	view →
COAD	OS	Median	All	0.242	0.686	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SLC12A6–KIRC (DFS)

Open the KIRC breakdown →